Evidence map›Paper›PMID 23021024›Full record

ArticleVirology journal2012

IL-2 immunotherapy in chronically SIV-infected Rhesus macaques.

Julie Garibal, Mireille Laforge, Ricardo Silvestre, Shahul Mouhamad, Laure Campillo-Gimenez, Yves Lévy, Jérôme Estaquier

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Julie GaribalINSERM U955 Equipe 16, Institut Mondor de Recherche Biomédicale, Créteil, F-94010, France.
Mireille Laforge
Ricardo Silvestre
Shahul Mouhamad
Laure Campillo-Gimenez
Yves Lévy
Jérôme Estaquier
Inserm · FRInstitut Mondor de Recherche Biomédicale · FRDélégation Paris 5 · FRUniversidade do Porto · PTUniversité Laval · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite inducing a sustained increase in CD4+ T cell counts, intermittent recombinant IL-2 (rIL-2) therapy did not confer a better clinical outcome in HIV-infected patients enrolled in large phase III clinical trials ESPRIT and SILCAAT. Several hypotheses were evoked to explain these discrepancies. Here, we investigated the impact of low and high doses of IL-2 in Rhesus macaques of Chinese origin infected with SIVmac251 in the absence of antiretroviral therapy (ART).

resultsWe demonstrated that rIL-2 induced a dose dependent expansion of CD4+ and CD8+ T cells without affecting viral load. rIL-2 increased CD4 and CD8 Treg cells as defined by the expression of CD25(high)FoxP3(+)CD127(low). We also showed that rIL-2 modulated spontaneous and Fas-mediated CD4(+) and CD8(+) T cell apoptosis. The higher dose exhibited a dramatic pro-apoptotic effect on both CD4(+) and CD8(+) T cell populations. Finally, all the animals treated with rIL-2 developed a wasting syndrome in the month following treatment simultaneously to a dramatic decrease of circulating effector T cells.

conclusionThese data contribute to the understanding of the homeostatic and dosage effects of IL-2 in the context of SIV/HIV infection.

Indexed as

AnimalsApoptosisCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDisease Models, AnimalImmunologic FactorsImmunotherapyInterleukin-2Lymphocyte CountMacaca mulattaSimian Acquired Immunodeficiency SyndromeT-Lymphocytes, RegulatoryTreatment OutcomeViral LoadImmunologic FactorsInterleukin-2

Identifiers

PMID23021024
PMCPMC3499432
OpenAlexW2164265306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.